Professor Wang

CONTACT

Lead Sponsor

The First Affiliated Hospital of Zhengzhou University

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

No

•1. Subjects participate voluntarily and sign informed consent.
•2. 18-75 years, male or female.
•3. Histologically or cytologically verified diagnosis of unresectable locally advanced or metastatic esophageal squamous cell carcinoma
•4. Patients who have disease progression verified by imaging on standard first-line immunotherapy with anti-PD-1/PD-L1 antibodies
•5. At least 1 measurable target lesion according to Response Evaluation in Solid Tumors (RECIST 1.1).
•6. ECOG PS 0-1

•1. Presence of any active autoimmune disease or history of autoimmune disease (such as: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hypophysitis, nephritis, hyperthyroidism)
•2. Those who are taking immunosuppressants or systemic hormonal therapy for immunosuppressive purposes (dose\> 10 mg/day prednisone or other equivalent cortiremonial hormones) and are taking within 2 weeks before recruitment
•3. Severe allergic reaction to other monoclonal antibodies
•4. Those who terminated treatment due to related toxicity during anti-PD-1/PD-L1 antibody treatment
•5. Prior treatment with bispecific anti-PD-1/CTLA-4 checkpoint blockades or VEGFR inhibitors

Related studies

NCT07463573 · Esophageal Squamous Cell Carcinoma (ESCC)

NCT07359417 · Esophageal Squamous Cell Carcinoma (ESCC), Esophageal Cancer, Squamous Cell

NCT05473156 · Locally Advanced or Metastatic Solid Tumors, Non Small Cell Lung Cancer (NSCLC), and more

NCT06710665 · Esophageal Squamous Cell Carcinoma (ESCC)

NCT06709417 · Esophageal Squamous Cell Carcinoma (ESCC)

Efficacy and Safety of QL1706 Plus Lenvatinib As 2nd Line Theapy in Patients with Metastatic Esophageal Carcinoma After Disease Progression on ICIs Therapy